BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27292441)

  • 1. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
    Morgado M; Carson DD
    J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
    Morgado M; Sutton MN; Simmons M; Warren CR; Lu Z; Constantinou PE; Liu J; Francis LL; Conlan RS; Bast RC; Carson DD
    Oncotarget; 2016 Mar; 7(12):14871-84. PubMed ID: 26918940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I; Garde-Granger P; Bessette P; Piché A
    BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
    Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
    Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth.
    Pon CK; Firth SM; Baxter RC
    Mol Cell Endocrinol; 2015 Jan; 399():354-61. PubMed ID: 25449421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
    Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
    Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
    Seargent JM; Yates EA; Gill JH
    Br J Pharmacol; 2004 Dec; 143(8):933-7. PubMed ID: 15533890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
    Reinartz S; Failer S; Schuell T; Wagner U
    Eur J Cancer; 2012 Jul; 48(10):1558-69. PubMed ID: 21852110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Boivin M; Lane D; Piché A; Rancourt C
    Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.
    Mody M; Dharker N; Bloomston M; Wang PS; Chou FS; Glickman TS; McCaffrey T; Yang Z; Pumfery A; Lee D; Ringel MD; Pinzone JJ
    Endocr Relat Cancer; 2007 Jun; 14(2):305-15. PubMed ID: 17639046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor β/δ and γ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation.
    Blitek A; Szymanska M
    Theriogenology; 2020 Aug; 152():36-46. PubMed ID: 32361305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.
    Wang P; Dharmaraj N; Brayman MJ; Carson DD
    Mol Endocrinol; 2010 Jul; 24(7):1368-79. PubMed ID: 20484415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells.
    Woster AP; Combs CK
    J Neurochem; 2007 Oct; 103(1):67-76. PubMed ID: 17573821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
    Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
    Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
    Pseftogas A; Gonidas C; Mosialos G
    Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans-10, cis-12 conjugated linoleic acid and the PPAR-γ agonist rosiglitazone attenuate lipopolysaccharide-induced TNF-α production by bovine immune cells.
    Perdomo MC; Santos JE; Badinga L
    Domest Anim Endocrinol; 2011 Oct; 41(3):118-25. PubMed ID: 21798687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
    J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
    Rao TD; Rosales N; Spriggs DR
    Mol Cancer Ther; 2011 Oct; 10(10):1939-48. PubMed ID: 21817115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.